Target Families: The Nuclear Receptor Superfamily and Drug Discovery

Chemical Biology: From Small Molecules to Systems Biology and Drug Design, Volume 1-3

Volumn 3, Issue , 2008, Pages 891-932

  Moore, John T ^a   Collins, Jon L ^a   Pearce, Kenneth H ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

(glucocorticoid deficiency); Antiestrogens; Coactivator; Peroxisome proliferator; Selective peroxisome

Indexed keywords

EID: 84891282346     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619375.ch15c     Document Type: Chapter

References (129)

1. Nuclear Receptors Nomenclature, C., A unified nomenclature system for the nuclear receptor superfamily, Cell 1999, 97, 161-163.
2. O. Wrange, J.A Gustafsson, Separation of the hormone-and DNA-binding sites of the hepatic glucocorticoid receptor by means of proteolysis, J. Biol. Chem. 1978, 253, 856-865.
3. J.M. Wurtz, W. Bourguet, J.P. Renaud, V. Vivat, P. Chambon, D. Moras, H. Gronemeyer, A canonical structure for the ligand-binding domain of nuclear receptors, Nat. Struct. Biol. 1996, 3, 87-94.
4. S. Khorasanizadeh, F. Rastinejad, Nuclear-receptor interactions on DNA-response elements, Trends Biochem. Sei. 2001, 26, 384-390.
5. W. Bourguet, M. Ruff, P. Chambon, H. Gronemeyer, D. Moras, Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha [see comment], Nature 1995, 375, 377-382.
6. S.P. Williams, P.B Sigler, Atomic structure of progesterone complexed with its receptor, Nature 1998, 393, 392-396.
7. B.F. Luisi, W.X. Xu, Z. Otwinowski, L.P. Freedman, K.R. Yamamoto, P.B Sigler, Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA, Nature 1991, 352, 497-505.
8. M.I. Diamond, J.N. Miner, S.K. Yoshinaga, K.R Yamamoto, Transcription factor interactions: selectors of positive or negative regulation from a single DNA element, Science 1990, 249, 1266-1272.
9. R.F. Witzmann, Steroids, Keys to Life, 1981.
10. M.J. Coghlan, S.W. Elmore, P.R. Kym, M.E Kort, The pursuit of differentiated ligands for the glucocorticoid receptor, Curr. Top. Med. Chem. 2003, 3, 1617-1635.
11. R.B. Woodward, F. Sondheimer, D. Taub, The total synthesis of cortisone, J. Am. Chem. Soc. 1951, 73, 4057.
12. L.H. Sarett, G.E. Arth, R.M. Lukes, R.E. Beyler, G.I. Poos, W.F. Johns, J.M Constantin, Stereospecific total synthesis of cortisone, J. Am. Chem. Soc. 1952, 74, 4974-4976.
13. V.C. Jordan, Tamoxifen: a most unlikely pioneering medicine [see comment], Nat. Rev. Drug Discov. 2003, 2, 205-213.
14. R. Miesfeld, S. Okret, A.C. Wikstrom, O. Wrange, J.A. Gustafsson, K.R Yamamoto, Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells, Nature 1984, 312, 779-781.
15. M.V. Govindan, M. Devic, S. Green, H. Gronemeyer, P. Chambon, Cloning of the human glucocorticoid receptor cDNA, Nucleic Acids Res. 1985, 13, 8293-8304.
16. S.M. Hollenberg, C. Weinberger, E.S. Ong, G. Cerelli, A. Oro, R. Lebo, E.B. Thompson, M.G. Rosenfeld, R.M Evans, Primary structure and expression of a functional human glucocorticoid receptor cDNA, Nature 1985, 318, 635-641.
17. S. Green, P. Walter, G. Greene, A. Krust, C. Goffin, E. Jensen, G. Scrace, M. Waterfield, P. Chambon, Cloning of the human oestrogen receptor cDNA, J. Steroid Biochem. 1986, 24, 77-83.
18. P. Walter, S. Green, G. Greene, A. Krust, J.M. Bornert, J.M. Jeltsch, A. Staub, E. Jensen, G. Scrace, M. Waterfield, P. Chambon, Cloning of the human estrogen receptor cDNA, Proc. Natl. Acad. Sei. U.S.A. 1985, 82, 7889-7893.
19. G.L. Greene, P. Gilna, M. Waterfield, A. Baker, Y. Hort, J. Shine, Sequence and expression of human estrogen receptor complementary DNA, Science 1986, 231, 1150-1154.
20. D.J. Mangelsdorf, R.M Evans, The RXR heterodimers and orphan receptors, Cell 1995, 83, 841-850.
21. B. Blumberg, R.M Evans, Orphan nuclear receptors-new ligands and new possibilities, Genes Dev. 1998, 12, 3149-3155.
22. V. Giguere, Orphan nuclear receptors: from gene to function, Endocr. Rev. 1999, 20, 689-725.
23. S.A. Kliewer, J.T. Moore, L. Wade, J.L. Staudinger, M.A. Watson, S.A. Jones, D.D. McKee, B.B. Oliver, T.M. Willson, R.H. Zetterstrom, T. Perlmann, J.M Lehmann, An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway, Cell 1998, 92, 73-82.
24. M. Kobayashi, S. Takezawa, K. Hara, R.T. Yu, Y. Umesono, K. Agata, M. Taniwaki, K. Yasuda, K. Umesono, Identification of a photoreceptor cell-specific nuclear receptor, Proc. Natl. Acad. Sei. U.S.A. 1999, 96, 4814-4819.
25. J.M. Magiích, A.E. Sluder, T.M. Willson, J.T Moore, Beyond the human genome: examples of nuclear receptor analysis in model organisms and potential for drug discovery, Am. J. Pharmacogenomics 2003, 3, 345-353.
26. M. Robinson-Rechavi, A.S. Carpentier, M. Duffraisse, V. Laudet, How many nuclear hormone receptors are there in the human genome? Trends Genet. 2001, 17, 554-556.
27. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, S.A Kliewer, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma), J. Biol. Chem. 1995, 270, 12953-12956.
28. D.J. Parks, S.G. Blanchard, R.K. Bledsoe, G. Chandra, T.G. Consler, S.A. Kliewer, J.B. Stimmel, T.M. Willson, A.M. Zavacki, D.D. Moore, J.M Lehmann, Bile acids: natural ligands for an orphan nuclear receptor [see comment], Science 1999, 284, 1365-1368.
29. R.K. Bledsoe, V.G. Montana, T.B. Stanley, C.J. Delves, C.J. Apolito, D.D. McKee, T.G. Consler, D.J. Parks, E.L. Stewart, T.M. Willson, M.H. Lambert, J.T. Moore, K.H. Pearce, H.E Xu, Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition, Cell 2002, 120, 93-105.
30. R.K. Bledsoe, K.P. Madauss, J.A. Holt, C.J. Apolito, M.H. Lambert, K.H. Pearce, T.B. Stanley, E.L. Stewart, R.P. Trump, T.M. Willson, S.P Williams, A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor, J. Biol. Chem. 2005, 280, 31283-31293.
31. P.M. Matias, P. Donner, R. Coelho, M. Thomaz, C. Peixoto, S. Macedo, N. Otto, S. Joschko, P. Scholz, A. Wegg, S. Basler, M. Schafer, U. Egner, M.A Carrondo, Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations, J. Biol. Chem. 2000, 275, 26164-26171.
32. G.G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, J.A Gustafsson, Cloning of a novel receptor expressed in rat prostate and ovary, Proc. Natl. Acad. Sei. U.S.A. 1996, 93, 5925-5930.
33. A.C. Pike, A.M. Brzozowski, R.E Hubbard, A structural biologist's view of the oestrogen receptor, J. Steroid Biochem. Mol. Biol. 2000, 74, 261-268.
34. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, D.A. Agard, G.L Greene, The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen, Cell 1998, 95, 927-937.
35. A.C.W. Pike, A.M. Brzozowski, R.E. Hubbard, T. Bonn, A.G. Thorsell, O. Engstrom, J. Ljunggren, J.K. Gustafsson, M. Carlquist, Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist, EMBO J. 1999, 18, 4608-4618.
36. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G.L. Greene, J.A. Gustafsson, M. Carlquist, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature 1997, 389, 753-758.
37. A.K. Shiau, D. Barstad, J.T. Radek, M.J. Meyers, K.W. Nettles, B.S. Katzenellenbogen, J.A. Katzenellenbogen, D.A. Agard, G.L Greene, Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism, Nat. Struct. Biol. 2002, 9, 359-364.
38. A.C.W. Pike, A.M. Brzozowski, J. Walton, R.E. Hubbard, A.G. Thorsell, Y.L. Li, J.A. Gustafsson, M. Carlquist, Structural insights into the mode of action of a pure antiestrogen, Structure 2001, 9, 145-153.
39. J.L. Oberfield, J.L. Collins, C.P. Holmes, D.M. Goreham, J.P. Cooper, J.E. Cobb, J.M. Lenhard, E.A. Hull-Ryde, C.P. Mohr, S.G. Blanchard, D.J. Parks, L.B. Moore, J.M. Lehmann, K. Plunket, A.B. Miller, M.V. Milburn, S.A. Kliewer, T.M Willson, A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation, Proc. Natl. Acad. Sei. U.S.A. 1999, 96, 6102-6106.
40. R.T. Nolte, G.B. Wisely, S. Westin, J.E. Cobb, M.H. Lambert, R. Kurokawa, M.G. Rosenfeld, T.M. Willson, C.K. Glass, M.V Milburn, Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma, Nature 1998, 395, 137-143.
41. S. Svensson, T. Ostberg, M. Jacobsson, C. Norstrom, K. Stefansson, D. Hallen, I.C. Johansson, K. Zachrisson, D. Ogg, L. Jendeberg, Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation, EMBO J. 2003, 22, 4625-4633.
42. S. Williams, R.K. Bledsoe, J.L. Collins, S. Boggs, M.H. Lambert, A.B. Miller, J. Moore, D.D. McKee, L. Moore, J. Nichols, D. Parks, M. Watson, B. Wisely, T.M. Willson, X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch, J. Biol. Chem. 2003, 278, 27138-27143.
43. M. Farnegardh, T. Bonn, S. Sun, J. Ljunggren, H. Ahola, A. Wilhelmsson, J.A. Gustafsson, M. Carlquist, The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands, J. Biol. Chem. 2003, 278, 38821-38828.
44. G.B. Wisely, A.B. Miller, R.G. Davis, A.D. Thornquest Jr, R. Johnson, T. Spitzer, A. Sefler, B. Shearer, J.T. Moore, T.M. Willson, S.P Williams, Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids, Structure 2002, 10, 1225-1234.
45. Z. Wang, G. Benoit, J. Liu, S. Prasad, P. Aarnisalo, X. Liu, H. Xu, N.P. Walker, T. Perlmann, Structure and function of Nurrl identifies a class of ligand-independent nuclear receptors, Nature 2003, 423, 555-560.
46. S. Dhe-Paganon, K. Duda, M. Iwamoto, Y.I. Chi, S.E Shoelson, Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand, J. Biol. Chem. 2002, 277, 37973-37976.
47. K.D. Baker, L.M. Shewchuk, T. Kozlova, M. Makishima, A. Hassell, B. Wisely, J.A. Caravella, M.H. Lambert, J.L. Reinking, H. Krause, C.S. Thummel, T.M. Willson, D.J Mangelsdorf, The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway, Cell 2003, 113, 731-742.
48. D.P. McDonnell, D.L. Clemm, T. Hermann, M.E. Goldman, J.W Pike, Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens, Mo J. Endocrinol. 1995, 9, 659-669.
49. H.E. Xu, T.B. Stanley, V.G. Montana, M.H. Lambert, B.G. Shearer, J.E. Cobb, D.D. McKee, C.M. Galardi, K.D. Plunket, R.T. Nolte, D.J. Parks, J.T. Moore, S.A. Kliewer, T.M. Willson, J.B Stimmel, Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha, Nature 2002, 415, 813-817.
50. B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K. Calles, AM.O. Engstr, J. Harlan, S. Muchmore, A.K. Ramqvist, S. Thorell, L. Ohman, J. Greer, J.A. Gustafsson, J. Carlstedt-Duke, M. Carlquist, The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism, J. Biol. Chem. 2003, 278, 22748-22754.
51. B.A. Johnson, E.M. Wilson, Y. Li, D.E. Moller, R.G. Smith, G. Zhou, Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation, J. Mol. Biol. 2000, 298, 187-194.
52. M. Beato, J. Klug, Steroid hormone receptors: an update, Hum. Reprod. Update 2000, 6, 225-236.
53. H. Gronemeyer, J.A. Gustafsson, V. Laudet, Principles for modulation of the nuclear receptor superfamily, Nat. Rev. Drug Discov. 2004, 3, 950-964.
54. W.B. Pratt, The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor, J. Biol. Chem. 1993, 268, 21455-21458.
55. S.A. Onate, S.Y. Tsai, M.J. Tsai, B.W. O'Malley, Sequence and characterization of a coactivator for the steroid hormone receptor superfamily, Science 1995, 270, 1354-1357.
56. C.K. Glass, D.W. Rose, M.G Rosenfeld, Nuclear receptor coactivators, Curr. Opin. Cell Biol. 1997, 9, 222-232.
57. J.W. Lee, Y.C. Lee, S.Y. Na, D.J. Jung, S.K Lee, Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors, Cell. Mol. Life Sei. 2001, 58, 289-297.
58. N.J. McKenna, B.W. O'Malley, Minireview: nuclear receptor coactivators-an update [Review], Endocrinology 2002, 143, 2461-2465.
59. D.M. Heery, E. Kalkhoven, S. Hoare, M.G Parker, A signature motif in transcriptional co-activators mediates binding to nuclear receptors [see comment], Nature 1997, 387, 733-736.
60. D.M. Heery, S. Hoare, S. Hussain, M.G. Parker, H. Sheppard, Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors, J. Biol. Chem. 2001, 276, 6695-6702.
61. T.E. Spencer, G. Jenster, M.M. Burcin, C.D. Allis, J. Zhou, C.A. Mizzen, N.J. McKenna, S.A. Onate, S.Y. Tsai, M.J. Tsai, B.W. O'Malley, Steroid receptor coactivator-1 is a histone acetyltransferase, Nature 1997, 389, 194-198.
62. M.L. Privalsky, The role of corepressors in transcriptional regulation by nuclear hormone receptors, Annu. Rev. Physiol. 2004, 66, 315-360.
63. J.D. Chen, R.M Evans, A transcriptional co-repressor that interacts with nuclear hormone receptors [see comment], Nature 1995, 377, 454-457.
64. A.J. Horlein, A.M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Soderstrom, C.K. Glass, M.G. Rosenfeld, Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor [see comment], Nature 1995, 377, 397-404.
65. M.G. Guenther, O. Barak, M.A Lazar, The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3, Mol. Cell. Biol. 2001, 21, 6091-6101.
66. X. Hu, M.A Lazar, The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors, Nature 1999, 402, 93-96.
67. M. Gottlicher, S. Heck, P. Herrlich, Transcriptional cross-talk, the second mode of steroid hormone receptor action [see comment], J. Mol. Med. 1998, 76, 480-489.
68. L.I. McKay, J.A. Cidlowski, Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism, Mol. Endocrinol. 1998, 12, 45-56.
69. L.I. McKay, J.A Cidlowski, Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways, Endocr. Rev. 1999, 20, 435-459.
70. A. Ray, K.E. Prefontaine, P. Ray, Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor, J. Biol. Chem. 1994, 269, 12940-12946.
71. A. Ray, K.E Prefontaine, Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor, Proc. Natl. Acad. Sei. U.S.A. 1994, 91, 752-756.
72. E. Caldenhoven, J. Liden, S. Wissink, A. Van de Stolpe, J. Raaijmakers, L. Koenderman, S. Okret, J.A. Gustafsson, P.T. Van der Saag, Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids, Mol. Endocrinol. 1995, 9, 401-412.
73. V. Doucas, Y. Shi, S. Miyamoto, A. West, I. Verma, R.M Evans, Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor, Proc. Natl. Acad. Sei. U.S.A. 2000, 97, 11893-11898.
74. R. Lösel, M. Wehling, Nongenomic actions of steroid hormones, Nat. Rev. Mol. Cell Biol. 2003, 4, 46-56.
75. V. Boonyaratanakornkit, M.P. Scott, V. Ribon, L. Sherman, S.M. Anderson, J.L. Maller, W.T. Miller, D.P Edwards, Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases, MoL Cells 2001, 8, 269-280.
76. M.A. Shupnik, Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation, Oncogene 2004, 23, 7979-7989.
77. C.Z. Song, X. Tian, T.D Gelehrter, Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3, Proc. Natl. Acad. Sei. U.S.A. 1999, 96, 11776-11781.
78. A. Bruna, M. Nicolas, A. Munoz, J.M. Kyriakis, C. Caelles, Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids, EMBO J. 2003, 22, 6035-6044.
79. T. Simoncini, A. Hafezi-Moghadam, D.P. Brazil, K. Ley, W.W. Chin, J.K Liao, Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase, Nature 2000, 407, 538-541.
80. S. Kato, Estrogen receptor-mediated cross-talk with growth factor signaling pathways, Breast Cancer 2001, 8, 3-9.
81. J. Bastien, C. Rochette-Egly, Nuclear retinoid receptors and the transcription of retinoid-target genes, Gene 2004, 328, 1-16.
82. C. Rochette-Egly, Nuclear receptors: integration of multiple signalling pathways through phosphorylation, Cell. Signalling 2003, 15, 355-366.
83. D.A. Lannigan, Estrogen receptor phosphorylation, Steroids 2003, 68, 1-9.
84. R.R. Love, R.B. Mazess, H.S. Barden, S. Epstein, P.A. Newcomb, V.C. Jordan, P.P. Carbone, D.L DeMets, Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comment], N. Engl. J. Med. 1992, 326, 852-856.
85. P.D. Delmas, N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, M. Draper, C. Christiansen, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [see comment], N. Engl. J. Med. 1997, 337, 1641-1647.
86. S.M. Ismail, The effects of tamoxifen on the uterus, Curr. Opin. Obstet. Gynecol. 1996, 8, 27-31.
87. C.H. Turner, M. Sato, H.U Bryant, Raloxifene preserves bone strength and bone mass in ovariectomized rats, Endocrinology 1994, 135, 2001-2005.
88. D.P. McDonnell, The molecular pharmacology of SERMs, Trends Endocrinol. Metab. 1999, 10, 301-311.
89. Y. Shang, M. Brown, Molecular determinants for the tissue specificity of SERMs [see comment], Science 2002, 295, 2465-2468.
90. P. Webb, P. Nguyen, P.J Kushner, Differential SERM effects on corepressor binding dictate ERalpha activity in vivo, J. Biol. Chem. 2003, 278, 6912-6920.
91. T.M. Willson, B.R. Henke, T.M. Momtahen, P.S. Charifson, K.W. Batchelor, D.B. Lubahn, L.B. Moore, B.B. Oliver, H.R. Sauls, J.A. Triantafillou, S.G. Wolfe, P.G. Baer, 3-(4-(1, 2-Diphenylbut-l-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats, J. Med. Chem. 1994, 37, 1550-1552.
92. T.M. Willson, J.D. Norris, B.L. Wagner, I. Asplin, P. Baer, H.R. Brown, S.A. Jones, B. Henke, H. Sauls, S. Wolfe, D.C. Morris, D.P McDonnell, Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone, Endocrinology 1997, 138, 3901-3911.
93. C.E. Connor, J.D. Norris, G. Broadwater, T.M. Willson, M.M. Gottardis, M.W. Dewhirst, D.P McDonnell, Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor, Cancer Res. 2001, 61, 2917-2922.
94. H.U. Bryant, Selective estrogen receptor modulators, Rev. Endocr. Metab. Disord. 2002, 3, 231-241.
95. M.J. Meegan, D.G Lloyd, Advances in the science of estrogen receptor modulation, Curr. Med. Chem. 2003, 10, 181-210.
96. C.C. Chadwick, S. Chippari, E. Matelan, L. Borges-Marcucci, A.M. Eckert, J.C. Keith Jr, L.M. Albert, Y. Leathurby, H.A. Harris, R.A. Bhat, M. Ashwell, E. Trybulski, R.C. Winneker, S.J. Adelman, R.J. Steffan, D.C Harnish, Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity, Proc. Natl. Acad. Sei. U.S.A. 2005, 102, 2543-2548.
97. J.A. Gustafsson, What pharmacologists can learn from recent advances in estrogen signalling, Trends Pharmacol. Sei. 2003, 24, 479-485.
98. B.R. Henke, T.G. Consler, N. Go, R.L. Hale, D.R. Hohman, S.A. Jones, A.T. Lu, L.B. Moore, J.T. Moore, L.A. Orband-Miller, R.G. Robinett, J. Shearin, P.K. Spearing, E.L. Stewart, P.S. Turnbull, S.L. Weaver, S.P. Williams, G.B. Wisely, M.H Lambert, A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta, J. Med. Chem. 2002, 45, 5492-5505.
99. H.A. Harris, J.A. Katzenellenbogen, B.S Katzenelnbogen, Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand, Endocrinology 2002, 143, 4172-4177.
100. E.S. Manas, R.J. Unwalla, Z.B. Xu, M.S. Malamas, C.P. Miller, H.A. Harris, C. Hsiao, T. Akopian, W.T. Hum, K. Malakian, S. Wolfrom, A. Bapat, R.A. Bhat, M.L. Stahl, W.S. Somers, J.C. Alvarez, Structure-based design of estrogen receptor-beta selective ligands, J. Am. Chem. Soc. 2004, 126, 15106-15119.
101. H.M. Reichardt, K.H. Kaestner, J. Tuckermann, O. Kretz, O. Wessely, R. Bock, P. Gass, W. Schmid, P. Herrlich, P. Angel, G. Schutz, DNA binding of the glucocorticoid receptor is not essential for survival, Cell 1998, 93, 531-541.
102. B.R. Walker, Deflazacort: towards selective glucocorticoid receptor modulation? Clin. Endocrinol. 2000, 52, 13-15.
103. B.M. Vayssiere, S. Dupont, A. Choquart, F. Petit, T. Garcia, C. Marchandeau, H. Gronemeyer, M. Resche-Rigon, Synthetic glucocorticoids that dissociate transactivation and AP-I transrepression exhibit antiinflammatory activity in vivo, Mol. Endocrinol. 1997, 11, 1245-1255.
104. S.W. Elmore, M.J. Coghlan, D.D. Anderson, J.K. Pratt, B.E. Green, A.X. Wang, M.A. Stashko, C.W. Lin, C.M. Tyree, J.N. Miner, P.B. Jacobson, D.M. Wilcox, B.C Lane, Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2, 5-dihydro-10-methoxy-2, 2, 4-trimethyl-lH-[l]benzopyrano[3, 4-f]quinolines, J. Med. Chem. 2001, 44, 4481-4491.
105. S.W. Elmore, J.K. Pratt, M.J. Coghlan, Y. Mao, B.E. Green, D.D. Anderson, M.A. Stashko, C.W. Lin, D. Falls, M. Nakane, L. Miller, C.M. Tyree, J.N. Miner, B. Lane, Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators, Bioorg. Med. Chem. Lett. 2004, 14, 1721-1727.
106. H. Schacke, A. Schottelius, W.D. Docke, P. Strehlke, S. Jaroch, N. Schmees, H. Rehwinkel, H. Hennekes, K. Asadullah, Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects, Proc. Natl. Acad. Sei. U.S.A. 2004, 101, 227-232.
107. D. DeManno, W. Elger, R. Garg, R. Lee, B. Schneider, H. Hess-Stumpp, G. Schubert, K. Chwalisz, Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy, Steroids 2003, 68, 1019-1032.
108. B.J. Barnes, P.A. Howard, Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure, Ann. Pharmacother. 2005, 39, 68-76.
109. J.A. Delyani, Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology, Kidney Int. 2000, 57, 1408-1411.
110. J.P. Heaton, Andropause: coming of age for an old concept? Curr. Opin. Urol. 2001, 11, 597-601.
111. R.S. Tan, S.J. Pu, J.W Culberson, Role of androgens in mild cognitive impairment and possible interventions during andropause, Med. Hypotheses 2004, 62, 14-18.
112. A.F. Santos, H. Huang, D.J Tindall, The androgen receptor: a potential target for therapy of prostate cancer, Steroids 2004, 69, 79-85.
113. J. Rosen, A. Negro-Vilar, Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile, J. Musculoskelet. Neuronal Interact. 2002, 2, 222-224.
114. J.P. Berger, A.E. Petro, K.L. Macnaul, L.J. Kelly, B.B. Zhang, K. Richards, A. Elbrecht, B.A. Johnson, G. Zhou, T.W. Doebber, C. Biswas, M. Parikh, N. Sharma, M.R. Tanen, G.M. Thompson, J. Ventre, A.D. Adams, R. Mosley, R.S. Surwit, D.E. Moller, Mol. Endocrinol. 2003, 17, 662-676.
115. M. Downes, M.A. Verdecia, A.J. Roecker, R. Hughes, J.B. Hogenesch, H.R. Kast-Woelbern, M.E. Bowman, J.L. Ferrer, A.M. Anisfeld, P.A. Edwards, J.M. Rosenfeld, J.G. Alvarez, J.P. Noel, K.C. Nicolaou, R.M Evans, A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR [see comment], Mol. Cells 2003, 11, 1079-1092.
116. E.M. Quinet, D.A. Savio, A.R. Halpern, L. Chen, C.P. Miller, P. Nambi, Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor, J. Lipid Res. 2004, 45, 1929-1942.
117. B. Miao, S. Zondlo, S. Gibbs, D. Cromley, V.P. Hosagrahara, T.G. Kirchgessner, J. Billheimer, R. Mukherjee, Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator, J. Lipid Res. 2004, 45, 1410-1417.
118. S. Folkertsma, P. van Noort, J. Van Durme, H.J. Joosten, E. Bettler, W. Fleuren, L. Oliveira, F. Horn, J. De Vlieg, G. Vriend, A family-based approach reveals the function of residues in the nuclear receptor ligand-binding domain, J. Mol. Biol. 2004, 341, 321-335.
119. J.D. Baxter, J.W. Funder, J.W. Apriletti, P. Webb, Towards selectively modulating mineralocorticoid receptor function: lessons from other systems, Mol. Cell. Endocrinol. 2004, 217, 151-165.
120. J.D. Norris, L.A. Paige, D.J. Christensen, C.Y. Chang, M.R. Huacani, D. Fan, P.T. Hamilton, D.M. Fowlkes, D.P McDonnell, Peptide antagonists of the human estrogen receptor, Science 1999, 285, 744-746.
121. M.A. Iannone, C.A. Simmons, S.H. Kadwell, D.L. Svoboda, D.E. Vanderwall, S.-J. Deng, T.G. Consler, J. Shearin, J.G. Gray, K.H Pearce, Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor modulating compounds, Mol. Endocrinol. 2004, 18, 1064-1081.
122. K.H. Pearce, M.A. Iannone, C.A. Simmons, J.G Gray, Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling, Drug Discov. Today 2004, 9, 741-751.
123. F. Stossi, D.H. Barnett, J. Frasor, B. Komm, C.R. Lyttle, B.S Katzenellenbogen, Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors, Endocrinology 2004, 145, 3473-3486.
124. M. Kian Tee, I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R.J. Christy, K.R. Yamamoto, D.C Leitman, Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta, Mol. Biol. Cell 2004, 15, 1262-1272.
125. P.E. Young, D.K. Bol, High-throughput transcriptional profiling for drug discovery and lead development, Genet. Eng. News 2003, 23.
126. M. Huber, I. Bahr, J.R. Kratzschmar, A. Becker, E.C. Muller, P. Donner, H.D. Pohlenz, M.R. Schneider, A. Sommer, Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r, Mol. Cell. Proteomics 2004, 3, 43-55.
127. M. Podvinec, M.R. Kaufmann, C. Handschin, U.A. Meyer, NUBIScan, an in silico approach for prediction of nuclear receptor response elements, Mol. Endocrinol. 2002, 16, 1269-1279.
128. V.X. Jin, Y.W. Leu, S. Liyanarachchi, H. Sun, M. Fan, K.P. Nephew, T.H. Huang, R.V Davuluri, Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray, Nucleic Acids Res. 2004, 32, 6627-6635.
129. H. Escriva, S. Bertrand, V. Laudet, The evolution of the nuclear receptor superfamily, Essays Biochem. 2004, 40, 11-26.